NeuroOne Medical Technologies Corporation (NMTC) – What Are Investment Firms Saying About This Stock?

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has earned an average rating of “Hold” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $7.33.

A number of equities research analysts have recently weighed in on NMTC shares. Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Maxim Group set a $5.00 price target on NeuroOne Medical Technologies and gave the company a “buy” rating in a research note on Friday, August 14th.

Insider Activity

In related news, insider David Wambeke acquired 33,333 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were bought at an average cost of $2.01 per share, with a total value of $66,999.33. Following the completion of the transaction, the insider directly owned 199,999 shares of the company’s stock, valued at $401,997.99. This trade represents a 20.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On NeuroOne Medical Technologies

A number of large investors have recently bought and sold shares of NMTC. Susquehanna International Group LLP purchased a new stake in NeuroOne Medical Technologies in the second quarter valued at $41,000. BlackRock Inc. acquired a new stake in NeuroOne Medical Technologies during the second quarter worth $76,000. Finally, Bard Associates Inc. acquired a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth about $929,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Stock Up 2.1%

Shares of NASDAQ:NMTC opened at $0.88 on Friday. The firm’s 50-day simple moving average is $1.21 and its 200-day simple moving average is $3.08. The company has a market cap of $8.01 million, a price-to-earnings ratio of -0.93 and a beta of 0.95. NeuroOne Medical Technologies has a fifty-two week low of $0.77 and a fifty-two week high of $6.12.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The firm had revenue of $1.97 million during the quarter, compared to analysts’ expectations of $2.17 million. NeuroOne Medical Technologies had a negative net margin of 71.50% and a negative return on equity of 128.12%. On average, research analysts forecast that NeuroOne Medical Technologies will post -0.39 EPS for the current year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) is a medical device company focused on developing thin-film electrode technology for neurological applications. Its products are designed to support the diagnosis, monitoring and treatment of disorders affecting the brain and nervous system.

The company’s product portfolio includes the Evo cortical and stereoelectroencephalography (sEEG) electrode systems, which are used by clinicians to record electrical activity in the brain and help evaluate patients with conditions such as epilepsy.